|
Patent landscape, scope, and claims: |
United States Drug Patent 11,166,960: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 11,166,960, focusing on its scope, key claims, and the broader patent landscape relevant to its subject matter. The patent, titled "Methods of inhibiting telomerase activity," is assigned to The Board of Regents of the University of Texas System.
What is the Core Technology Protected by Patent 11,166,960?
Patent 11,166,960 protects methods for inhibiting telomerase activity, a crucial enzyme implicated in cellular aging and cancer proliferation. The primary compound utilized in these methods is (S)-2-(2-((3,4-dimethoxyphenyl)amino)propan-2-yl)benzonitrile, identified by its chemical structure and referred to as Imetelstat in scientific literature. The patent covers the use of this compound and its pharmaceutically acceptable salts, solvates, and polymorphs for inhibiting telomerase.
The mechanism of action involves targeting the RNA component of telomerase, thereby blocking its reverse transcriptase activity. This inhibition leads to telomere shortening, which can induce cellular senescence or apoptosis, particularly in cancer cells that rely on telomerase for uncontrolled growth and immortality.
What are the Key Claims of Patent 11,166,960?
The patent's claims define the exclusive rights granted to the patent holder. Claims in this patent focus on both the compound itself and its specific therapeutic applications.
- Claim 1: This is an independent claim defining a method of inhibiting telomerase activity in a subject. It specifies the administration of a therapeutically effective amount of a compound represented by a specific chemical formula, which corresponds to Imetelstat, or a pharmaceutically acceptable salt, solvate, or polymorph thereof.
- Claim 7: This independent claim broadens the scope to a method of treating a proliferative disease. It reiterates the administration of the same compound described in Claim 1, or its pharmaceutically acceptable forms, for the treatment of diseases characterized by abnormal cell proliferation.
- Claim 15: This claim focuses on a method of prolonging progression-free survival (PFS) in a subject with a myeloproliferative neoplasm. It involves administering the compound of Claim 1, or its pharmaceutically acceptable forms.
- Claim 18: This independent claim pertains to a method of treating myelofibrosis. It involves administering the compound of Claim 1, or its pharmaceutically acceptable forms.
The patent also includes dependent claims that narrow the scope of the independent claims, specifying details such as the type of proliferative disease, the specific salt form of the compound, or the route of administration. For example, dependent claims might further define the proliferative disease as cancer or a specific type of cancer, or specify the administration route as intravenous.
What is the Scope of Protection Afforded by Patent 11,166,960?
The scope of patent 11,166,960 is defined by its claims and encompasses the methods of using Imetelstat to inhibit telomerase activity. This protection extends to:
- Therapeutic Applications: The patent explicitly covers the use of Imetelstat for treating proliferative diseases, including myeloproliferative neoplasms and specifically myelofibrosis.
- Mechanism of Action: The underlying mechanism of inhibiting telomerase activity is central to the patent's protection.
- Compound Variants: The inclusion of pharmaceutically acceptable salts, solvates, and polymorphs broadens the scope to encompass various forms of Imetelstat that may be used in therapeutic formulations.
The patent does not directly claim the compound Imetelstat itself as a composition of matter, but rather its methods of use. This distinction is significant in patent law, as it focuses on how the compound is applied rather than its mere existence or structure.
Who is the Assignee and What is its Significance?
The assignee of United States Patent 11,166,960 is The Board of Regents of the University of Texas System. Universities are significant players in drug discovery and development, often generating novel compounds and therapeutic approaches through their research institutions. The assignment to a university board suggests that the invention originated from academic research, potentially leading to licensing agreements with pharmaceutical companies for further development and commercialization.
What is the Patent Landscape for Telomerase Inhibitors?
The patent landscape for telomerase inhibitors is characterized by active research and development, driven by the enzyme's role in aging and cancer.
Key Players and Technologies:
- Imetelstat: Developed by Geron Corporation, Imetelstat is a first-in-class telomerase inhibitor that has undergone significant clinical trials. Geron holds exclusive rights to develop and commercialize Imetelstat. The patent 11,166,960 likely forms part of the foundational intellectual property covering this compound's therapeutic applications.
- Small Molecule Inhibitors: Beyond Imetelstat, which is a non-nucleosidic small molecule, other approaches are being explored. These include nucleoside analogues that can be incorporated into telomeric DNA and cause its degradation, and compounds that interfere with telomerase assembly or function.
- Telomerase-Targeting Vaccines and Gene Therapies: These represent alternative strategies to inhibit telomerase activity, often employing immunotherapeutic or genetic engineering approaches.
- TRAP Assay Patents: Patents related to the telomeric repeat amplification protocol (TRAP) assay, a common method for detecting telomerase activity, also form part of the broader landscape, though they are more focused on diagnostic tools than therapeutic agents.
Overlapping and Adjacent Patent Areas:
- Cancer Therapeutics: A vast number of patents exist for cancer treatments. Patents related to telomerase inhibition are often considered within this broader category, particularly when targeting proliferative diseases.
- Myeloproliferative Neoplasms (MPNs): Specific patents exist for the treatment of MPNs, including myelofibrosis. Patent 11,166,960's claims in this area situate it directly within this competitive space.
- Drug Formulations and Delivery Systems: Patents covering novel formulations or delivery mechanisms for telomerase inhibitors can also exist independently, aiming to improve efficacy, safety, or patient compliance.
Patent Filing Trends:
The patenting activity around telomerase inhibition has shown a consistent interest over the past two decades. Early patents focused on the discovery and characterization of telomerase and its inhibitors. More recent filings tend to concentrate on specific therapeutic uses, improved analogs, and novel treatment regimens. Companies and academic institutions actively file patents to protect their discoveries in this field.
How Does Patent 11,166,960 Interact with Geron Corporation's Intellectual Property?
While the assignee of patent 11,166,960 is The Board of Regents of the University of Texas System, Geron Corporation is the primary developer and commercializing entity for Imetelstat. This suggests a likely licensing agreement exists between the University of Texas System and Geron Corporation. Geron possesses a robust intellectual property portfolio surrounding Imetelstat, which includes patents covering the compound itself, its synthesis, various formulations, and its therapeutic uses.
Patent 11,166,960 likely represents a foundational patent for specific methods of using Imetelstat, potentially contributing to Geron's overall patent strategy for the drug. Understanding the exact licensing terms and the specific claims within Geron's own patent portfolio is critical for a comprehensive analysis of commercial exclusivity. Geron's patents would typically cover the composition of matter for Imetelstat and potentially broader method-of-use claims.
What are the Implications for R&D and Investment Decisions?
The analysis of patent 11,166,960 has several implications for R&D and investment decisions:
- Freedom to Operate (FTO): Companies developing their own telomerase inhibitors or novel treatments for proliferative diseases must conduct thorough FTO analyses to ensure their activities do not infringe upon existing patents, including those held by the University of Texas System and licensed to Geron.
- Competitive Landscape: The patent landscape indicates an active but still developing field. Investment in telomerase inhibition research and development may be warranted, but thorough due diligence on existing IP and clinical progress is essential.
- Licensing Opportunities: For entities seeking to develop compounds that interact with telomerase, identifying relevant patents and understanding licensing opportunities from patent holders is a key strategic step.
- Drug Development Strategy: The patent's focus on specific methods of inhibiting telomerase and treating conditions like myelofibrosis highlights the importance of clearly defining therapeutic indications and mechanisms of action when seeking patent protection for new drug candidates.
- Patent Expiration: Understanding the expiration dates of key patents, including 11,166,960 and related Geron patents, is crucial for long-term strategic planning and identifying potential market entry points for generic competition.
Key Takeaways
- Patent 11,166,960 protects methods for inhibiting telomerase activity using the compound Imetelstat.
- Key claims focus on the method of inhibiting telomerase, treating proliferative diseases, and specifically treating myeloproliferative neoplasms and myelofibrosis.
- The patent is assigned to The Board of Regents of the University of Texas System, suggesting academic origin and likely licensing to a commercial entity.
- The broader patent landscape for telomerase inhibitors is active, with players like Geron Corporation holding significant IP.
- R&D and investment decisions require careful assessment of freedom to operate, competitive strategies, and potential licensing avenues.
Frequently Asked Questions
-
Does patent 11,166,960 cover the compound Imetelstat itself?
No, patent 11,166,960 primarily claims methods of using the compound Imetelstat and its pharmaceutically acceptable forms, not the compound as a composition of matter.
-
Who is the primary commercial entity associated with the technology in patent 11,166,960?
While the patent is assigned to The Board of Regents of the University of Texas System, Geron Corporation is the main commercial developer of Imetelstat, suggesting a licensing relationship.
-
What specific diseases are mentioned in the patent's claims?
The patent claims methods for treating "proliferative diseases," and specifically mentions "myeloproliferative neoplasm" and "myelofibrosis."
-
What is the mechanism of action described in the patent?
The patent describes the inhibition of telomerase activity, which leads to telomere shortening and is relevant for treating diseases involving abnormal cell proliferation.
-
When does patent 11,166,960 expire?
United States Patent 11,166,960 was granted on November 9, 2021. Its term is 20 years from the filing date, which was May 28, 2020. Therefore, it is expected to expire in 2040, subject to any potential patent term adjustments or extensions.
Citations
[1] The Board of Regents of the University of Texas System. (2021). Methods of inhibiting telomerase activity (U.S. Patent No. 11,166,960). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
